GHK-Cu
Pending PCACAlso known as: Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II)
Anti-Aging & SkinLast reviewed: April 28, 2026
A naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Levels decline significantly with age. Widely used in both injectable and topical forms for anti-aging.
Mechanism of Action
Activates wound healing genes, promotes collagen and elastin synthesis, stimulates blood vessel growth, and has anti-inflammatory and antioxidant properties. The copper ion is essential for many enzymatic processes in tissue remodeling.
Common Uses
- Skin rejuvenation and anti-aging
- Wound healing
- Hair growth stimulation
- Collagen production
- Reducing inflammation
Known Risks
- Generally well-tolerated topically
- Injectable form has less safety data
- Potential copper toxicity at high doses
- Skin irritation possible with topical use
Regulatory Status
GHK-Cu has a notably complex status after the April 15, 2026 FDA announcement. Injectable GHK-Cu is being removed from Category 2 (significant safety risks), while non-injectable GHK-Cu is simultaneously being removed from Category 1 (active evaluation). Both forms are scheduled for a unified PCAC review before February 2027. Topical cosmetic use is unaffected. Injectable use is now in regulatory gray zone — compounding pharmacies should not assume authorization until PCAC acts.
Get notified when the PCAC decides on GHK-Cu
Scheduled review: By February 2027. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Topical (cream/serum)
Typical Dose
0.1–2% concentration
Frequency
Once or twice daily
Cycle Length
Ongoing — no cycling needed for topical
Most common and well-tolerated form. Apply to face, neck, or target area. Widely available in cosmetic products without prescription.
Subcutaneous injection
Typical Dose
1–2 mg
Frequency
2–3x per week
Cycle Length
4–8 weeks
Injectable form has less safety data than topical. Currently in regulatory gray zone following April 2026 FDA announcement — verify status before use.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.